Long Term Investment, Biotech & High Yield Dividend Stocks

[califax]

Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

http://www.finanznachrichten.de/nachrichten-2010-04/16737855-aeterna-zentaris-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement-008.htm

27.04.2010 16:46
Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

QUEBEC CITY, April 27 /PRNewswire-FirstCall/ -- Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, announced today that it has received a letter from the Nasdaq Stock Market notifying it that the closing price per share of the Company's common stock was above the US$1.00 minimum bid price for 10 consecutive trading days and that, as a result, the Company has regained compliance with Marketplace Rule 5450(a)(1) (the minimum bid price rule) as of Friday, April 23, 2010.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy News releases and additional information are available at http://www.aezsinc.com/.

AETERNA ZENTARIS INC.

CONTACT: Investor Relations: Ginette Vallieres, Investor Relations
Coordinator, [phone] ext. 265, [e-mail]; Media Relations:
Paul Burroughs, Director of Communications, [phone] ext. 406,
[e-mail]


© 2010 PR Newswire